Astrana Health, Inc. (NASDAQ:ASTH) Receives $53.29 Consensus Target Price from Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $53.29.

Several analysts recently weighed in on ASTH shares. Barclays started coverage on Astrana Health in a report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price target for the company. Bank of America reduced their price objective on Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Robert W. Baird lowered their target price on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Truist Financial lowered their price objective on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Finally, Stifel Nicolaus decreased their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC bought a new stake in Astrana Health in the 3rd quarter worth about $58,995,000. Principal Financial Group Inc. bought a new stake in shares of Astrana Health in the third quarter valued at $13,383,000. 325 Capital LLC raised its stake in shares of Astrana Health by 30.3% in the fourth quarter. 325 Capital LLC now owns 886,916 shares of the company's stock valued at $27,964,000 after buying an additional 206,009 shares during the period. Renaissance Technologies LLC lifted its position in shares of Astrana Health by 217.6% during the 4th quarter. Renaissance Technologies LLC now owns 217,900 shares of the company's stock valued at $6,870,000 after buying an additional 149,300 shares during the last quarter. Finally, Royce & Associates LP grew its stake in shares of Astrana Health by 122.3% during the 4th quarter. Royce & Associates LP now owns 255,552 shares of the company's stock worth $8,058,000 after acquiring an additional 140,584 shares during the period. Institutional investors own 52.77% of the company's stock.

Astrana Health Trading Up 1.0 %

ASTH traded up $0.30 during mid-day trading on Monday, hitting $31.20. The stock had a trading volume of 95,698 shares, compared to its average volume of 275,581. Astrana Health has a 1-year low of $23.12 and a 1-year high of $63.20. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of 23.95, a price-to-earnings-growth ratio of 1.37 and a beta of 1.04. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock's fifty day simple moving average is $31.49 and its 200-day simple moving average is $38.71.

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. As a group, research analysts forecast that Astrana Health will post 1.15 EPS for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.